Latest Insider Transactions at Nuvalent, Inc. (NUVL)
This section provides a real-time view of insider transactions for Nuvalent, Inc. (NUVL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Nuvalent, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Nuvalent, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 16
2025
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,700
-19.23%
|
$1,249,500
$85.1 P/Share
|
|
Jul 16
2025
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,700
+16.13%
|
$264,600
$18.93 P/Share
|
|
Jul 15
2025
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-2.5%
|
$2,241,000
$83.11 P/Share
|
|
Jul 15
2025
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+8.91%
|
$486,000
$18.93 P/Share
|
|
Jul 15
2025
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,300
-2.03%
|
$445,200
$84.23 P/Share
|
|
Jul 15
2025
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+7.33%
|
$95,400
$18.93 P/Share
|
|
Jul 10
2025
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,500
-4.15%
|
$440,000
$80.43 P/Share
|
|
Jul 10
2025
|
Henry E. Pelish Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+2.65%
|
$137,500
$25.37 P/Share
|
|
Jul 09
2025
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,145
-1.7%
|
$173,745
$81.49 P/Share
|
|
Jun 27
2025
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
20,000
-24.47%
|
$1,600,000
$80.02 P/Share
|
|
Jun 27
2025
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+19.66%
|
$360,000
$18.93 P/Share
|
|
Jun 27
2025
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,170
-3.32%
|
$171,430
$79.92 P/Share
|
|
Jun 27
2025
|
Henry E. Pelish Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,170
+1.63%
|
$60,760
$28.59 P/Share
|
|
Jun 26
2025
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,000
-2.58%
|
$312,000
$78.41 P/Share
|
|
Jun 26
2025
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+7.14%
|
$108,000
$27.85 P/Share
|
|
Jun 25
2025
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,630
-12.03%
|
$681,770
$79.87 P/Share
|
|
Jun 25
2025
|
Henry E. Pelish Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,630
+5.84%
|
$241,640
$28.59 P/Share
|
|
Jun 18
2025
|
James E Flynn Director |
BUY
Grant, award, or other acquisition
|
Indirect |
5,294
+50.0%
|
-
|
|
Jun 18
2025
|
Cameron Wheeler |
BUY
Grant, award, or other acquisition
|
Direct |
2,647
+33.97%
|
-
|
|
Jun 18
2025
|
Michael L. Meyers |
BUY
Grant, award, or other acquisition
|
Direct |
2,647
+33.97%
|
-
|
|
Jun 18
2025
|
Joseph Pearlberg |
BUY
Grant, award, or other acquisition
|
Direct |
2,647
+33.97%
|
-
|
|
Jun 18
2025
|
Anna Protopapas |
BUY
Grant, award, or other acquisition
|
Direct |
2,647
+33.97%
|
-
|
|
Jun 18
2025
|
Matthew Shair |
BUY
Grant, award, or other acquisition
|
Direct |
2,647
+0.18%
|
-
|
|
Jun 18
2025
|
Sapna Srivastava |
BUY
Grant, award, or other acquisition
|
Direct |
2,647
+33.97%
|
-
|
|
Jun 18
2025
|
Christy J. Oliger |
BUY
Grant, award, or other acquisition
|
Direct |
3,971
+50.0%
|
-
|
|
Jun 18
2025
|
Grant C. Bogle |
BUY
Grant, award, or other acquisition
|
Direct |
2,647
+31.16%
|
-
|
|
Jun 16
2025
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-3.34%
|
$2,079,000
$77.38 P/Share
|
|
Jun 16
2025
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+8.91%
|
$729,000
$27.85 P/Share
|
|
Jun 06
2025
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
200
-0.32%
|
$15,800
$79.82 P/Share
|
|
Jun 06
2025
|
Henry E. Pelish Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+0.16%
|
$5,600
$28.59 P/Share
|
|
May 29
2025
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,000
-3.88%
|
$284,000
$71.46 P/Share
|
|
May 29
2025
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+3.77%
|
$84,000
$21.13 P/Share
|
|
May 15
2025
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-3.35%
|
$1,890,000
$70.01 P/Share
|
|
May 15
2025
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+8.91%
|
$729,000
$27.85 P/Share
|
|
Apr 29
2025
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,000
-7.69%
|
$296,000
$74.56 P/Share
|
|
Apr 29
2025
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+7.14%
|
$56,000
$14.4 P/Share
|
|
Apr 15
2025
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-2.53%
|
$1,863,000
$69.54 P/Share
|
|
Apr 15
2025
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+8.91%
|
$729,000
$27.85 P/Share
|
|
Mar 27
2025
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,000
-3.9%
|
$292,000
$73.37 P/Share
|
|
Mar 27
2025
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+3.77%
|
$64,000
$16.67 P/Share
|
|
Mar 17
2025
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-3.34%
|
$2,052,000
$76.06 P/Share
|
|
Mar 17
2025
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+8.91%
|
$729,000
$27.85 P/Share
|
|
Mar 07
2025
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,000
-3.91%
|
$288,000
$72.13 P/Share
|
|
Mar 07
2025
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+7.14%
|
$4,000
$1.08 P/Share
|
|
Mar 06
2025
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
30,000
-14.18%
|
$2,130,000
$71.72 P/Share
|
|
Mar 06
2025
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+16.61%
|
$90,000
$3.99 P/Share
|
|
Feb 24
2025
|
Matthew Shair |
SELL
Open market or private sale
|
Indirect |
2,000
-0.31%
|
$156,000
$78.38 P/Share
|
|
Feb 18
2025
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-4.91%
|
$2,106,000
$78.73 P/Share
|
|
Feb 18
2025
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+8.91%
|
$729,000
$27.85 P/Share
|
|
Jan 31
2025
|
Henry E. Pelish Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,120
+4.71%
|
$0
$0.87 P/Share
|